Literature DB >> 31778150

Distal esophagus is the most commonly involved site for strictures in patients with eosinophilic esophagitis.

Swathi Eluri1,2, Manaswita Tappata3, Kevin Z Huang3, Nathaniel T Koutlas3, Benjamin S Robey3, Claire Fan3, Craig C Reed1,2, Nicholas J Shaheen1,2, Evan S Dellon1,2.   

Abstract

While strictures are common in eosinophilic esophagitis (EoE), there are few data on stricture distribution and characteristics. Our primary aim was to characterize strictures by location in the esophagus in EoE and associated clinical, endoscopic, and histologic features. This was a retrospective study from the UNC EoE Clinicopathologic Database of subjects with esophageal strictures or narrowing from 2002 to 2017. Strictures were categorized as distal esophagus/gastroesophageal junction, mid-esophagus, proximal esophagus, or diffusely narrowed. Stricture location was assessed and compared with clinical, endoscopic, and histologic features, and also with treatment response to diet or topical steroids. Efficacy of combination therapy with dilation and intralesional steroid injection was assessed in a sub-group of patients with strictures. Of 776 EoE cases, 219 (28%) had strictures, 45% of which were distal, 30% were proximal, 5% were mid-esophageal, and 20% had diffuse narrowing. Those with mid-esophageal strictures were younger (P = 0.02) and had shorter symptom duration (P < 0.01). Those with diffuse esophageal narrowing were more likely to be women (57%) and have abdominal pain (25%). There was no association between other clinical, endoscopic, and histologic findings and treatment response based on stricture location. Fourteen patients (8%) received intralesional triamcinolone injection and subsequently achieved a higher mean dilation diameter after injection (13.7 vs. 15.5 mm; P < 0.01). In conclusion, almost half of strictures in EoE patients were in the distal esophagus. Therefore, EoE should be a diagnostic consideration in patients with focal distal strictures and not presumed to be secondary to gastroesophageal reflux disease.
© The Author(s) 2019. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  dilation; eosinophilic esophagitis; stricture; triamcinolone

Mesh:

Year:  2020        PMID: 31778150     DOI: 10.1093/dote/doz088

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  5 in total

1.  British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.

Authors:  Anjan Dhar; Hasan N Haboubi; Stephen E Attwood; Marcus K H Auth; Jason M Dunn; Rami Sweis; Danielle Morris; Jenny Epstein; Marco R Novelli; Hannah Hunter; Amanda Cordell; Sharon Hall; Jamal O Hayat; Kapil Kapur; Andrew Robert Moore; Carol Read; Sarmed S Sami; Paul J Turner; Nigel J Trudgill
Journal:  Gut       Date:  2022-05-23       Impact factor: 31.793

2.  Optimizing the Endoscopic Examination in Eosinophilic Esophagitis.

Authors:  Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-29       Impact factor: 11.382

3.  Early life factors are associated with risk for eosinophilic esophagitis diagnosed in adulthood.

Authors:  Evan S Dellon; Olivia Shaheen; Nathaniel T Koutlas; Audrey O Chang; Lisa J Martin; Marc E Rothenberg; Elizabeth T Jensen
Journal:  Dis Esophagus       Date:  2021-02-10       Impact factor: 2.822

Review 4.  Formulations of Topical Steroids in Eosinophilic Esophagitis-Current Treatment and Emerging Possibilities.

Authors:  Adam Główczewski; Aneta Krogulska
Journal:  J Clin Med       Date:  2022-03-07       Impact factor: 4.241

5.  Worsened Fibrostenotic Outcomes in Eosinophilic Esophagitis Patients Due to COVID-19-Related Endoscopy Cancellations.

Authors:  Adolfo A Ocampo; Evan S Dellon
Journal:  Dig Dis Sci       Date:  2022-07-05       Impact factor: 3.487

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.